Danish medical company Allarity Therapeutics has divested the drug Irufulven to US-stocklisted company Lantern Pharma. The total price including an upfront payment and development and regulatory milestone fees may amount to around USD 18m, not including the royalties the company can earn from the sales, according to a Monday press release from the Danish company, which is listed in Sweden.
At first, Irufulven was developed by US MGI Pharma and Japanese Eisai, which ran the drug through phase III trials, although they did not manage to commercialize it.
Already a subscriber? Log in.
Read the whole article
Get 14 days free access.
No credit card required.
Get full access for you and your coworkers.
Start a free company trial todayMore from MedWatch
CHMP recommends nine new drugs, rejects one
Roche and Biogen are among the companies that have received recommendation for approval from the European Medicines Agency's committee (CHMP) at its September meeting. One Pfizer drug was the sole candidate to be rejected.
WS Audiology still chewing over listing of online hearing company
The hearing giant is still mulling over the independent listing of Hear.com.
CEO at WSA: No clarity on EQT exit plans yet
The time horizon for the venture fund EQT's investment in WS Audiology should be ending soon, but according to Group CEO Eric Bernard, there is no clarity on when the potential changes might occur.
Oticon: Covid-19 led to debates about product launches
The unpredictable world situation in the spring of 2020 meant that the timing of product launches was frequently discussed at Demant-owned Oticon, located in Denmark.
EU Commission ends Danish HERA dreams – but could provide new opportunities for the pharmaceutical industry
With a budget potentially exceeding EUR 47.1bn (DKK 350bn), the EU Commission wants to establish a new agency to ward against future health crises. While the financial makeup is uncertain, good news for future clinical trials might be on the way.
QA Specialist wanted 
Project Manager, Adcendo ApS 
Senior Clinical Research Specialist - Ambu 
Principal Scientist, Protein Drug Discovery & Development - Y-mAbs Therapeutics A/S 
Senior Manager, QA GMP - Genmab 
Senior Downstream Scientist - Symphogen 
Employee of the regulatory department with knowledge of food safety and legislation within dietary supplements and medicines 
Medical Director (diabetes and obesity) - Zealand Pharma 
Director of Communications – Evaxion Biotech 
Global Senior Medical Advisor – Neurology Pipeline Projects, Lundbeck 
Senior QA Specialist - Vaccibody 
KLIFO is looking for a talented Medical Writer (DK, SE or DE)